Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

Crawford, 1990, Hormonal therapy of prostatic carcinoma. Defining the challenge, Cancer, 66, 1035, 10.1002/cncr.1990.66.s5.1035

Sharifi, 1990, Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer, J Urol, 143, 68, 10.1016/S0022-5347(17)39868-3

Sogani, 1987, Treatment of advanced prostatic cancer, Urol Clin North Am, 14, 353, 10.1016/S0094-0143(21)00575-9

Schally, 1992, Present status of agonistic and antagonistic analogs of LHRH in the treatment of advanced prostate cancer, Biomed Pharmacother, 46, 465, 10.1016/0753-3322(92)90004-Q

Schally, 1993, Hypothalamic and other peptide hormones, 827

Bajusz, 1988, Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects, Proc Natl Acad Sci USA, 85, 1637, 10.1073/pnas.85.5.1637

Bajusz, 1988, New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues, Int J Pept Protein Res, 32, 425, 10.1111/j.1399-3011.1988.tb01373.x

Schally, 1990, New antagonistic analogues of LHRH: experimental oncological and clinical studies. Advances in the study of GnRH analogues. The basic science of GnRH analogues, 2, 25

Gonzalez-Barcena, 1994, Inhibition of LH, FSH and sex-steroid levels in men and women with a potent antagonistic analog of LHRH, cetrorelix (SB-75), Eur J Endocrinol, 131, 286, 10.1530/eje.0.1310286

Gonzalez-Barcena, 21241989, Inhibition of LH and FSH release in hypergonadotropic patients with new potent antagonists of LH-RH free of anaphylactoid reactions, Endocrine Society Annual Meeting, Seattle, Washington, 450

Gonzalez-Barcena, 20231990, Potent antagonistic analog of LH-RH (SB-75) inhibits LH, FSH, and testosterone levels in human beings., Program and abstracts of the 72nd Annual Meeting, Endocrine Society, Atlanta, Georgia, 354

Gonzalez-Barcena, 1992, Response to the antagonistic analog of LH-RH (SB-75) in patients with benign prostatic hyperplasia (BPH) and prostatic cancer, Endocrine Society Meeting program and abstracts, San Antonio, Texas, 1992, 53

Gonzalez-Barcena, 1993, Treatment of patients with advanced prostatic cancer with LH-RH antagonist SB-75 and of the relapse by the combination of agonist D-Trp-6-LH-RH and somatostatin analog RC-160, Program and abstracts of the Annual Meeting Endocrine Society, Las Vegas, Nevada, 389

Gonzalez-Barcena, 1994, Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer, Prostate, 24, 84, 10.1002/pros.2990240206

Hendrikx, 1988, Effectiveness of ultrasound in the preoperative evaluation of patients with prostatism, Prostate, 13, 199, 10.1002/pros.2990130302

Byrne, 1992, Spinal cord compression from epidural metastases, N Engl J Med, 327, 614, 10.1056/NEJM199208273270907

Barron, 1959, Experiences with metastatic neoplasms involving the spinal cord, Neurology, 9, 91, 10.1212/WNL.9.2.91

Gilbert, 1978, Epidural spinal cord compression from metastatic tumor: diagnosis and treatment, Ann Neurol, 3, 40, 10.1002/ana.410030107

Constans, 1983, Spinal metastases with neurological manifestations: review of 600 cases, J Neurosurg, 59, 111, 10.3171/jns.1983.59.1.0111

Stark, 1982, Spinal metastases a retrospective survey from a general hospital, Brain, 105, 189, 10.1093/brain/105.1.189

Labrie, 1987, Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist, J Urol, 138, 804, 10.1016/S0022-5347(17)43380-5

Kuhn, 1984, Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide), N Engl J Med, 321, 413, 10.1056/NEJM198908173210701

Kahan, 1984, Disease flare induced by D-Trp 6-LHRH analogue in patients with metastatic prostatic cancer, Lancet, I, 971, 10.1016/S0140-6736(84)92435-8

Mahler, 1988, Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostate cancer, Am J Clin Oncol, 11, S127, 10.1097/00000421-198801102-00032

Szende, 1990, Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75, J Natl Cancer Inst, 82, 513, 10.1093/jnci/82.6.513

Korkut, 1991, Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75, Proc Natl Acad Sci USA, 88, 844, 10.1073/pnas.88.3.844

Redding, 1992, Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice, Cancer Res, 52, 2538

Szende, 1990, Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists, Cancer Res, 50, 3716

Andreyko, 1992, Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonistic (detirelix), J Clin Endocrinol Metab, 74, 399, 10.1210/jc.74.2.399

Pavlou, 1987, Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in men, J Clin Endocrinol Metab, 64, 931, 10.1210/jcem-64-5-931

Rabinovici, 1992, Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women, J Clin Endocrinol Metab, 75, 1220, 10.1210/jc.75.5.1220

Pavlou, 1989, Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men, J Clin Endocrinol Metab, 68, 446, 10.1210/jcem-68-2-446

Jockenhovel, 1988, Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men, J Clin Endocrinol Metab, 66, 1065, 10.1210/jcem-66-5-1065

Leal, 1988, Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist, J Clin Endocrinol Metab, 67, 1325, 10.1210/jcem-67-6-1325

Matikainen, 1992, Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women, J Clin Endocrinol Metab, 75, 820, 10.1210/jc.75.3.820

Bagatell, 1993, Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men, Fertil Steril, 60, 680, 10.1016/S0015-0282(16)56222-0

Behre, 1992, Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men, J Clin Endocrinol Metab, 75, 393, 10.1210/jc.75.2.393

Klingmuller, 1993, Hormonal responses to the new potent GnRH antagonist cetrorelix, Acta Endocrinol (Copenh), 128, 15, 10.1530/acta.0.1280015

Oesterling, 1993, Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor, J Urol, 149, 779, 10.1016/S0022-5347(17)36206-7

Ploch, 1994, How to use prostate-specific antigen, Urology, 43, 27, 10.1016/0090-4295(94)90215-1

Stamey, 1989, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: IV. Anti-androgen treated patients, J Urol, 141, 1088, 10.1016/S0022-5347(17)41177-3